ADC Therapeutics SA – Product Pipeline Review

Global Markets Direct’s, ‘ADC Therapeutics SA – Product Pipeline Review – 2016’, provides an overview of the ADC Therapeutics SA’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by ADC Therapeutics SA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of ADC Therapeutics SA

The report provides overview of ADC Therapeutics SA including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses ADC Therapeutics SA’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features ADC Therapeutics SA’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate ADC Therapeutics SA’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for ADC Therapeutics SA

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding ADC Therapeutics SA’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

ADC Therapeutics SA Snapshot 5

ADC Therapeutics SA Overview 5

Key Facts 5

ADC Therapeutics SA - Research and Development Overview 6

Key Therapeutic Areas 6

ADC Therapeutics SA - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

ADC Therapeutics SA - Pipeline Products Glance 11

ADC Therapeutics SA - Clinical Stage Pipeline Products 11

Phase I Products/Combination Treatment Modalities 11

ADC Therapeutics SA - Early Stage Pipeline Products 12

Preclinical Products/Combination Treatment Modalities 12

Discovery Products/Combination Treatment Modalities 13

ADC Therapeutics SA - Drug Profiles 14

ADCT-301 - Drug Profile 14

Product Description 14

Mechanism Of Action 14

R&D Progress 14

ADCT-401 - Drug Profile 16

Product Description 16

Mechanism Of Action 16

R&D Progress 16

ADCT-402 - Drug Profile 17

Product Description 17

Mechanism Of Action 17

R&D Progress 17

ADCT-501 - Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

ADCT-502 - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

ADCT-601 - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

Monoclonal Antibody Conjugate for Oncology - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

Monoclonal Antibody Conjugate to Target CD22 for Non Hodgkin's Lymphoma - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

Monoclonal Antibody Conjugates 1 for Oncology - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

Monoclonal Antibody Conjugates to Target PSMA for Prostate Cancer - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

VM-101 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

ADC Therapeutics SA - Pipeline Analysis 27

ADC Therapeutics SA - Pipeline Products by Target 27

ADC Therapeutics SA - Pipeline Products by Route of Administration 28

ADC Therapeutics SA - Pipeline Products by Molecule Type 29

ADC Therapeutics SA - Pipeline Products by Mechanism of Action 30

ADC Therapeutics SA - Dormant Projects 31

ADC Therapeutics SA - Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Appendix 33

Methodology 33

Coverage 33

Secondary Research 33

Primary Research 33

Expert Panel Validation 33

Contact Us 33

Disclaimer 34

List of Tables

List of Tables

ADC Therapeutics SA, Key Facts 5

ADC Therapeutics SA – Pipeline by Indication, 2016 8

ADC Therapeutics SA – Pipeline by Stage of Development, 2016 9

ADC Therapeutics SA – Monotherapy Products in Pipeline, 2016 10

ADC Therapeutics SA – Phase I, 2016 11

ADC Therapeutics SA – Preclinical, 2016 12

ADC Therapeutics SA – Discovery, 2016 13

ADC Therapeutics SA – Pipeline by Target, 2016 27

ADC Therapeutics SA – Pipeline by Route of Administration, 2016 28

ADC Therapeutics SA – Pipeline by Molecule Type, 2016 29

ADC Therapeutics SA – Pipeline Products by Mechanism of Action, 2016 30

ADC Therapeutics SA – Dormant Developmental Projects,2016 31

ADC Therapeutics SA, Other Locations 32

List of Figures

List of Figures

ADC Therapeutics SA – Pipeline by Top 10 Indication, 2016 7

ADC Therapeutics SA – Pipeline by Stage of Development, 2016 9

ADC Therapeutics SA – Monotherapy Products in Pipeline, 2016 10

ADC Therapeutics SA – Pipeline by Target, 2016 27

ADC Therapeutics SA – Pipeline by Molecule Type, 2016 29

ADC Therapeutics SA – Pipeline Products by Mechanism of Action, 2016 30

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports